Site Map
-
Welcome
- Our Medicines
-
Resources
- Formulary packs
- Videos
-
Publications
-
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials1
- SWORD Studies
- FLAMINGO study (96-week data)
- SPRING-2 study (96-week data)
- SAILING study (48-week data)
- SINGLE study (144-week data)
-
- Posters
- Slide Sets
- HIV Guidelines
- Therapy Area
-
News & Events
-
News
- CROI 2019 - TD/TND dolutegravir▼+ lamivudine
- CROI 2019 - Lamidol
- CROI 2019 - Dawning sub-analysis
- Glasgow 2018—2-drug regimen
- Glasgow 2018—Comparable viral decay
- Glasgow 2018 Comparison of viral replication
- Glasgow 2018 Comparison of viral replication
- ARIA at International AIDS Conference 2016
- STRIIVING at International AIDS Conference 2016
- ViiV at the 23rd Annual Conference of the British HIV Association
- IAS 2017—NEAT022 PI/r Switch Lipid Study 48 Week data
- IAS 2017—DAWNING interim data
- IAS 2017—OPERA observational database
-
News
- I am a patient
- Contact a ViiV Healthcare Advisor
- Report an Adverse Event
- Privacy Policy
- Terms and Conditions
- Cookie Policy